COVID-19 Experiences in the SELF Cohort
NCT05369611
COVID-19, Coronaviridae Infections
Bethesda, Maryland, United States
View Trial DetailsNCT Number: NCT04285801
The purpose of this case series is to describe the characteristics, organ dysfunction and support and 2 week outcomes of critically ill patients with nCov infection.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Pamela Youde Nethersole Eastern Hospital, Hong Kong
The 2019 novel-coronavirus (2019-nCov) is the cause of a cluster of unexplained pneumonia that started in Hubei province in China 1. It has manifest into a global health crisis with escalating confirmed cases and spread across 15 countries. Whilst it is currently an epidemic in China, The World Health Organization (WHO) Global Level risk assessment is set at high 2.
Sequencing showed that 2019-nCov is similar to bat severe acute syndrome (SARS)-related coronaviruses found in Chinese horseshoe bats 3. This is compatible with the initial epidemiological link with a local wet market which sells bats. Furthermore, data sharing and sequencing data has facilitated development of accurate diagnostic tests.
In contrast, our current understanding of the epidemiological and clinical features of 2019-nCov is limited. In a case series of 41 hospitalized patients with confirmed infection, at least 30% of these patients required critical care admission. These patients developed severe respiratory failure and 10% required mechanical ventilation and 5% needed extracorporeal membrane oxygenation support. More worryingly 2019-nCov infection was associated with 15% mortality. Although these figures are likely overestimates due to unreported mild cases, there is currently no effective treatment. The optimal supportive care for patients with severe 2019-nCov infection is a research priority.
The spread of the 2019-nCov epidemic to Hong Kong has started. Patients have been admitted to the Intensive Care Unit for multiorgan dysfunction. Currently there are no published data focused specifically on critically ill patients with nCov infection. The purpose of this case series is to describe the characteristics, organ dysfunction and support and 2 week outcomes of critically ill patients with nCov infection.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 28 days
survival or death at 28 days
Time frame: 28 days
days on vasopressor
Time frame: 28 days
days on mechanical ventilation during ICU stay
Time frame: daily for first 5 days
daily sequential organ function assessment score (0 minimum to 24 maximum), higher scores worse organ function
Time frame: 28 days
Percentage of patients requiring ECMO during ICU stay.
Time frame: 28 days
percentage of patients requiring nitric oxide during ICU stay.
Time frame: 28 days
percentage not requiring oxygen therapy
Looking for future studies?
Notify MeChinese University of Hong Kong
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05369611
COVID-19, Coronaviridae Infections
Bethesda, Maryland, United States
View Trial DetailsNCT07834073
COVID-19, Coronaviridae Infections
Nanjing, China
View Trial DetailsNCT05886816
COVID-19, Coronaviridae Infections
Dallas, Texas, United States
View Trial DetailsNCT06928051
COVID-19, Coronaviridae Infections
Hot Springs, Arkansas, United States
View Trial Details